文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症革兰阴性菌医院获得性肺炎早期恰当抗菌治疗的预后影响:多中心队列研究

Prognostic Impact of Early Appropriate Antimicrobial Therapy in Critically Ill Patients With Nosocomial Pneumonia Due to Gram-Negative Pathogens: A Multicenter Cohort Study.
PubMed 文献 · Crit Care Med · 2025-02-26
一句话结论在32个法国ICU的804例革兰阴性菌HAP/vHAP/VAP患者中,早期恰当抗菌治疗与28天死亡率无独立关联(aHR 0.87,95%CI 0.67-1.12),但因统计效能不足不能排除获益。

该回顾性队列研究基于前瞻性收集的数据,纳入法国32个ICU(OutcomeRéa网络)中ICU期间首次发生革兰阴性菌所致HAP、vHAP或VAP的全部患者,共804例,其中495例(61.6%)接受早期恰当抗菌治疗(单药25.4%、联合36.2%)。主要终点28天全因死亡率为32.6%,早期恰当抗菌治疗与28天死亡率无独立关联(校正HR 0.87,95%CI 0.67-1.12),亚组分析及考虑ICU期间所有肺炎发作的第二个模型均证实该结果。早期恰当抗菌治疗与SOFA评分下降更快(P=0.11)、第14天临床治愈率更高(总体43.7%)、机械通气时间更短(拔管原因别HR 0.84,95%CI 0.69-1.01)或ICU住院时间更短(存活出院原因别HR 0.85,95%CI 0.72-1.00)均无关。作者认为,由于统计效能不足,不能排除早期恰当抗菌治疗的预后获益。

要点

  • 804例革兰阴性菌HAP/vHAP/VAP患者中,495例(61.6%)接受早期恰当抗菌治疗,28天死亡率为32.6%。
  • 早期恰当抗菌治疗与28天死亡率无独立关联:校正HR 0.87(95%CI 0.67-1.12)。
  • 亚组分析(按肺炎类型、致病革兰阴性菌、早期恰当抗菌治疗特征、诊断时脓毒性休克)及考虑ICU期间所有肺炎发作的第二个模型均证实上述结果。
  • 早期恰当抗菌治疗与SOFA评分下降更快无关(P=0.11),与第14天临床治愈率更高无关(总体43.7%)。
  • 早期恰当抗菌治疗与拔管原因别HR 0.84(95%CI 0.69-1.01)、存活出院原因别HR 0.85(95%CI 0.72-1.00)相关,均未达统计学显著。

适用人群与场景

  • 法国32个ICU(OutcomeRéa网络)中ICU期间首次发生革兰阴性菌所致医院获得性肺炎(HAP)、通气相关HAP(vHAP)或呼吸机相关肺炎(VAP)的全部患者。

研究设计与关键结果

  • 研究类型:基于前瞻性收集数据的回顾性队列研究,纳入32个法国ICU(OutcomeRéa网络)的804例ICU期间首次发生革兰阴性菌所致HAP、vHAP或VAP的患者。
  • 早期恰当抗菌治疗情况:495例(61.6%)接受早期恰当抗菌治疗,其中单药25.4%、联合36.2%。
  • 主要终点:28天全因死亡率为32.6%;早期恰当抗菌治疗与28天死亡率无独立关联(校正HR 0.87,95%CI 0.67-1.12)。
  • 亚组分析(按肺炎类型、致病革兰阴性菌、早期恰当抗菌治疗特征、诊断时脓毒性休克)及考虑ICU期间所有肺炎发作的第二个模型均证实主要结果。
  • 次要终点:早期恰当抗菌治疗与SOFA评分下降更快无关(P=0.11)。
  • 次要终点:第14天临床治愈率总体为43.7%,早期恰当抗菌治疗与之无关。
  • 次要终点:早期恰当抗菌治疗与机械通气时间更短无关(拔管原因别HR 0.84,95%CI 0.69-1.01)。
  • 次要终点:早期恰当抗菌治疗与ICU住院时间更短无关(存活出院原因别HR 0.85,95%CI 0.72-1.00)。

证据类型、等级与局限

  • 证据类型:基于前瞻性收集数据的回顾性队列研究。
  • 局限:作者指出,由于统计效能不足,不能排除早期恰当抗菌治疗的预后获益。

对床旁实践的改变

  • 作者认为,在本研究人群中,早期恰当抗菌治疗与28天死亡率降低、器官衰竭更快缓解、第14天临床治愈率更高或机械通气脱机及ICU出院时间更短均无关。
  • 作者认为,由于统计效能不足,不能排除早期恰当抗菌治疗的预后获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate whether early appropriate antimicrobial therapy (EAAT) is associated with improved outcomes in critically ill patients with hospital-acquired pneumonia (HAP), ventilated HAP (vHAP), or ventilator-associated pneumonia (VAP) involving Gram-negative bacteria (GNB).

DESIGN: Retrospective cohort study based on prospectively collected data.

SETTING: Thirty-two French ICUs (OutcomeRéa network).

PATIENTS: All patients with a first HAP, vHAP, or VAP due to GNB during their ICU stay.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: The relationship between EAAT and day 28 all-cause mortality (primary endpoint) was explored through Cox proportional-hazard models, with subgroup analyses according to pneumonia types, causative GNB, features of EAAT, and the occurrence of septic shock at pneumonia diagnosis. The course of Sequential Organ Failure Assessment (SOFA) score values, the clinical cure rate at day 14, and the time to mechanical ventilation (MV) weaning and ICU discharge after pneumonia diagnosis were investigated as secondary endpoints. Among the 804 included patients, 495 (61.6%) received EAAT (single-drug, 25.4%; combination, 36.2%). Day 28 mortality was 32.6%. EAAT was not independently associated with this outcome (adjusted hazard ratio, 0.87; 95% CI, 0.67-1.12). This result was confirmed in subgroup analyses as in a second model considering all episodes of pneumonia occurring during the ICU stay. EAAT was not associated with a faster decrease in SOFA score values ( p = 0.11), a higher day 14 clinical cure rate (overall, 43.7%), or a shorter MV duration (cause-specific hazard ratio [HR] for extubation, 0.84; 95% CI, 0.69-1.01) or ICU stay (cause-specific HR for discharge alive, 0.85; 95% CI, 0.72-1.00).

CONCLUSIONS: In this study, EAAT was not associated with a reduced day 28 mortality, a faster resolution of organ failure, a higher day 14 clinical cure rate, or a shorter time to MV weaning or ICU discharge in critically ill patients with HAP, vHAP, or VAP due to GNB. However, a prognostic benefit from EAAT cannot be ruled out due to lack of statistical power.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Barbier F, Buetti N, Dupuis C, et al. Prognostic Impact of Early Appropriate Antimicrobial Therapy in Critically Ill Patients With Nosocomial Pneumonia Due to Gram-Negative Pathogens: A Multicenter Cohort Study. Crit Care Med. 2025. PMID: 40009040. doi:10.1097/CCM.0000000000006606

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。